Press Release Archive

November 6, 2012 - U.S. Food and Drug Administration Approval of XELJANZ® (tofacitinib citrate) and Invitation to Media Briefing from Pfizer

U.S. Food and Drug Administration Approval of XELJANZ® (tofacitinib citrate) and Invitation to Media Briefing from Pfizer 11/6/12 5:25 pm ESTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ® (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate. XELJANZ may be used as monotherapy or in combination with methotrexate or other non-biologic disease-modifying antirheumatic drugs (DMARDs).

November 6, 2012 - U.S. Food And Drug Administration Approves Pfizer’s XELJANZ® (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Methotrexate

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate. XELJANZ may be used as monotherapy or in combination with methotrexate or other non-biologic disease-modifying antirheumatic drugs (DMARDs).

November 1, 2012 - Bristol-Myers Squibb and Pfizer Announce New Data on Stroke Prevention in Atrial Fibrillation to be Presented at American Heart Association 2012 Scientific Sessions

(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that a large number of data presentations sponsored by the companies on ELIQUIS® (apixaban) and the treatment of atrial fibrillation will be presented at the American Heart Association 2012 Scientific Sessions, November 3-7, 2012, in Los Angeles, California. Among the presentations are two prespecified subanalyses from the ARISTOTLE trial: a more detailed

November 1, 2012 - Portola, Bristol-Myers Squibb and Pfizer Sign Clinical Collaboration Agreement to Study ELIQUIS® and Portola’s Universal Factor Xa Inhibitor Antidote PRT4445

(BUSINESS WIRE)--Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor ELIQUIS® (apixaban). PRT4445 is a universal Factor Xa inhibitor antidote in clinical development designed to reverse the anticoagulant activity of any Factor Xa inhibitor. No agents are approved

October 31, 2012 - Grantmakers In Aging Receives $1.3 million from the Pfizer Foundation to Boost ‘Age-friendly’ Communities

(BUSINESS WIRE)--In partnership with the Pfizer Foundation, Grantmakers In Aging (GIA), a national association of funders, today launched Community AGEnda: Improving America for All Ages, announcing five grants of $150,000 each to local groups in Arizona, Florida, Georgia, Indiana, and the greater Kansas City area to accelerate their efforts to become “age-friendly” – that is, great places to grow up and grow old. “The aging of America’s population is

October 31, 2012 - Pfizer Reports Third-Quarter 2012 Results

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE): ($ in millions, except per share amounts) Third-Quarter Year-to-Datemore...

October 28, 2012 - Pfizer Reschedules Issuance Of Third Quarter 2012 Performance Report And Associated Conference Call And Webcast to November 1, 2012 Due To Expected Severe Weather Conditions

(BUSINESS WIRE)--Pfizer Inc. announces the postponement of the issuance of its Third Quarter 2012 Performance Report and webcast of a conference call with investment analysts, which was previously scheduled for Tuesday, October 30, 2012 at 10 a.m. EDT, due to the expected severe weather conditions associated with Hurricane Sandy. The webcast of a conference call with investment analysts has been rescheduled for Thursday, November 1, 2012 at 10 a.m. EDTmore...

October 25, 2012 - Pfizer Declares A 22-Cent Fourth-Quarter 2012 Dividend

(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared a 22-cent fourth-quarter 2012 dividend on the company’s common stock, payable December 4, 2012, to shareholders of record at the close of business on November 9, 2012. The fourth-quarter 2012 cash dividend will be the 296th consecutive quarterly dividend paid by Pfizer. more...

October 24, 2012 - Pfizer’s XALKORI® Receives Conditional Marketing Authorization from the European Commission for the Treatment of Adults with Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer in the EU

(BUSINESS WIRE)--Pfizer Inc. announced today that the European Commission has given conditional marketing authorization for XALKORI® (crizotinib) in the European Union (EU) for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). “In the field of metastatic non-small cell lung cancer, XALKORI represents a major advancement. It brings to the patients with ALK-more...

October 21, 2012 - Pfizer To Acquire NextWave Pharmaceuticals, Inc.

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced its intention to acquire NextWave Pharmaceuticals, a privately held, specialty pharmaceutical company focused on the development and commercialization of unique products for the treatment of attention deficit/hyperactivity disorder (ADHD) and related central nervous system (CNS) disorders. NextWave is the developer of Quillivant XR™ (methylphenidate hydrochloride) for extended-release oralmore...

October 17, 2012 - Pfizer Consumer Healthcare Responds to PHS II Findings with Statement and Centrum® Silver® Multivitamin B-roll and Photo Assets

(BUSINESS WIRE)--Pfizer Consumer Healthcare: Wednesday, October 17 Wednesday, October 17 Wednesday, October 17more...

October 16, 2012 - Pfizer Announces Top-line Results From Phase 3 Trial Of INLYTA® (axitinib) In Treatment-Naïve Patients With Advanced Renal Cell Carcinoma

(BUSINESS WIRE)--Pfizer Inc. announced today that a Phase 3 study of INLYTA® (axitinib) did not meet its primary endpoint of demonstrating statistically significantly longer progression-free survival (PFS), versus sorafenib, in treatment-naïve patients with advanced renal cell carcinoma (RCC). A preliminary review of the data showed that overall the median PFS for INLYTA exceeded the median PFS for sorafenib, but did not meet statisticalmore...

October 15, 2012 - New Study With CHANTIX®/CHAMPIX® (varenicline) Tablets Suggests Favorable Benefit-Risk Profile In Adult Smokers With Major Depressive Disorder

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the completion of a double-blind, placebo-controlled, randomized clinical trial designed to assess the efficacy and safety of CHANTIX®/CHAMPIX® (varenicline) 1 mg BID in comparison to placebo for smoking cessation in patients with a past or present diagnosis of Major Depressive Disorder (MDD). The study met its primary and secondary efficacy endpoints. Subjects in the varenicline group had a highermore...

October 10, 2012 - Pfizer Announces Top-Line Results From A Phase 3 Long-Term Safety Study Of ALO-02:

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced top-line results today from a Phase 3 open-label long-term safety study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic, non-cancer pain. The primary objective of the study was to evaluate the safety of ALO-02 administered for up to 12 months. The study showed that the adverse event profile was asmore...

October 9, 2012 - New Report Reveals Programs That Promote Healthy Ageing Can Help Reduce Rising Health Costs1

(BUSINESS WIRE)--In 2050, the number of people aged 60 years and older worldwide will increase from 605 million to nearly 2 billion.2 While it’s good news that people are living longer, the number of older adults who will be affected by long-term, chronic conditions will increase,1 leading to a serious economic consequence as healthcare costs rise: greater demand for care, but less income to support it.1 A new Pfizer-sponsored report from the Economistmore...

October 3, 2012 - Pfizer Announces Top-Line Results Of Prevenar 13® Phase 3 Trial In Adults 18 To 49 Years Of Age

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced top-line data assessing immunogenicity, tolerability and safety of Prevenar 13®* (Pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]) in adults 18 to 49 years of age. These data support a recent regulatory submission to expand the indication of Prevenar 13 in the European Union to include adults between 18 and 49 years old, and will be used to support similar planned submissions in othermore...

October 1, 2012 - ELIQUIS® (apixaban) Demonstrates Consistent Reductions in Stroke and Systemic Embolism, Major Bleeding and Mortality Compared to Warfarin in Patients with Nonvalvular Atrial Fibrillation at Varying Risk for Stroke and Bleeding

(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the reductions in stroke or systemic embolism, major bleeding and mortality demonstrated with ELIQUIS® compared to warfarin in the ARISTOTLE trial were consistent across a wide range of stroke and bleeding risk scores in patients with nonvalvular atrial fibrillation. These results of a subanalysis from the ARISTOTLE clinical trial were published

September 26, 2012 - FDA Acknowledges Receipt of Resubmission of the ELIQUIS® (apixaban) New Drug Application to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

(BUSINESS WIRE)--Bristol-Myers Squibb Company(NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission for ELIQUIS® (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). The FDA assigned a new Prescription Drug User Fee Act (PDUFA) goal date of March 17, 2013. The FDAmore...

September 21, 2012 - Pfizer Invites Public To View And Listen To Webcast Of October 30 Conference Call With Analysts

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 30, 2012. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2012 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer more...

September 20, 2012 - ELIQUIS® (apixaban) Receives CHMP Positive Opinion For The Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation

(BUSINESS WIRE)--Bristol-Myers Squibb (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that ELIQUIS® (apixaban) be granted approval for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) and one or more risk factors for stroke. The CHMP's positive opinionmore...

Press release archive foot note

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

Stay on top of Pfizer breaking news: Get News Alerts by RSS.

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

If you do not have Adobe^® Reader, download it here. It is available without charge from Adobe^®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.